Answers are grounded in this paper and cite their sources.
Compares pembrolizumab vs paclitaxel in previously treated G/GEJ cancer, suggesting potential benefits.
Background: Pembrolizumab showed promising antitumor activity and a manageable safety profile in patients with pretreated G/GEJ cancer in KEYNOTE-012 and KEYNOTE-059. KEYNOTE-061 (NCT02370498) was a global, open-label phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced G/GEJ adenocarcinoma that progressed after first-line chemotherapy containing platinum and fluoropyrimidine.
No takes yet. Share an insight, caveat, or question.
Shitara et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: